1	1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Introduction	_	_	NN	_	_	_	_	_


1	Clinically	_	_	RB	_	_	_	_	_
2	relevant	_	_	JJ	_	_	_	_	_
3	photodynamic	_	_	JJ	_	_	_	_	_
4	therapy	_	_	NN	_	_	_	_	_
5	(	_	_	-LRB-	_	_	_	_	_
6	PDT	_	_	NNP	_	_	_	_	_
7	)	_	_	-RRB-	_	_	_	_	_
8	was	_	_	VBD	_	_	_	_	_
9	introduced	_	_	VBN	_	_	_	_	_
10	about	_	_	RB	_	_	_	_	_
11	45	_	_	CD	_	_	_	_	_
12	years	_	_	NNS	_	_	_	_	_
13	ago	_	_	RB	_	_	_	_	_
14	as	_	_	IN	_	_	_	_	_
15	a	_	_	DT	_	_	_	_	_
16	novel	_	_	JJ	_	_	_	_	_
17	means	_	_	NN	_	_	_	_	_
18	for	_	_	IN	_	_	_	_	_
19	selectively	_	_	RB	_	_	_	_	_
20	eradicating	_	_	VBG	_	_	_	_	_
21	a	_	_	DT	_	_	_	_	_
22	variety	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	solid	_	_	JJ	_	_	_	_	_
25	tumors	_	_	NNS	_	_	_	_	_
26	via	_	_	IN	_	_	_	_	_
27	cytotoxic	_	_	JJ	_	_	_	_	_
28	photochemistry	_	_	NN	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	As	_	_	IN	_	_	_	_	_
2	an	_	_	DT	_	_	_	_	_
3	anti-tumor	_	_	JJ	_	_	_	_	_
4	modality	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	PDT	_	_	NNP	_	_	_	_	_
7	is	_	_	VBZ	_	_	_	_	_
8	unique	_	_	JJ	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	requiring	_	_	VBG	_	_	_	_	_
11	three	_	_	CD	_	_	_	_	_
12	components	_	_	NNS	_	_	_	_	_
13	:	_	_	:	_	_	_	_	_
14	a	_	_	DT	_	_	_	_	_
15	photosensitizing	_	_	VBG	_	_	_	_	_
16	agent	_	_	NN	_	_	_	_	_
17	(	_	_	-LRB-	_	_	_	_	_
18	PS	_	_	NN	_	_	_	_	_
19	)	_	_	-RRB-	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	PS-exciting	_	_	JJ	_	_	_	_	_
22	light	_	_	NN	_	_	_	_	_
23	in	_	_	IN	_	_	_	_	_
24	the	_	_	DT	_	_	_	_	_
25	far-visible-to-near-infrared	_	_	JJ	_	_	_	_	_
26	range	_	_	NN	_	_	_	_	_
27	,	_	_	,	_	_	_	_	_
28	and	_	_	CC	_	_	_	_	_
29	molecular	_	_	JJ	_	_	_	_	_
30	oxygen	_	_	NN	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	PS	_	_	NN	_	_	_	_	_
2	photoexcitation	_	_	NN	_	_	_	_	_
3	during	_	_	IN	_	_	_	_	_
4	PDT	_	_	NNP	_	_	_	_	_
5	gives	_	_	VBZ	_	_	_	_	_
6	rise	_	_	NN	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	cytotoxic	_	_	JJ	_	_	_	_	_
9	reactive	_	_	JJ	_	_	_	_	_
10	oxygen	_	_	NN	_	_	_	_	_
11	species	_	_	NNS	_	_	_	_	_
12	(	_	_	-LRB-	_	_	_	_	_
13	ROS	_	_	NN	_	_	_	_	_
14	)	_	_	-RRB-	_	_	_	_	_
15	such	_	_	JJ	_	_	_	_	_
16	as	_	_	IN	_	_	_	_	_
17	singlet	_	_	NN	_	_	_	_	_
18	oxygen	_	_	NN	_	_	_	_	_
19	(	_	_	-LRB-	_	_	_	_	_
20	1O2	_	_	CD	_	_	_	_	_
21	)	_	_	-RRB-	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	first	_	_	JJ	_	_	_	_	_
3	PS	_	_	NN	_	_	_	_	_
4	to	_	_	TO	_	_	_	_	_
5	receive	_	_	VB	_	_	_	_	_
6	FDA	_	_	NNP	_	_	_	_	_
7	approval	_	_	NN	_	_	_	_	_
8	for	_	_	IN	_	_	_	_	_
9	PDT	_	_	NNP	_	_	_	_	_
10	applications	_	_	NNS	_	_	_	_	_
11	was	_	_	VBD	_	_	_	_	_
12	Photofrin®	_	_	NNP	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	an	_	_	DT	_	_	_	_	_
15	oligomeric	_	_	JJ	_	_	_	_	_
16	form	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	hematoporphyrin	_	_	NN	_	_	_	_	_
19	that	_	_	WDT	_	_	_	_	_
20	continues	_	_	VBZ	_	_	_	_	_
21	to	_	_	TO	_	_	_	_	_
22	be	_	_	VB	_	_	_	_	_
23	used	_	_	VBN	_	_	_	_	_
24	for	_	_	IN	_	_	_	_	_
25	a	_	_	DT	_	_	_	_	_
26	variety	_	_	NN	_	_	_	_	_
27	of	_	_	IN	_	_	_	_	_
28	malignancies	_	_	NNS	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	Unlike	_	_	IN	_	_	_	_	_
2	more	_	_	RBR	_	_	_	_	_
3	conventional	_	_	JJ	_	_	_	_	_
4	chemotherapy	_	_	NN	_	_	_	_	_
5	or	_	_	CC	_	_	_	_	_
6	radiotherapy	_	_	NN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	PDT	_	_	NNP	_	_	_	_	_
9	has	_	_	VBZ	_	_	_	_	_
10	few	_	_	JJ	_	_	_	_	_
11	(	_	_	-LRB-	_	_	_	_	_
12	if	_	_	IN	_	_	_	_	_
13	any	_	_	DT	_	_	_	_	_
14	)	_	_	-RRB-	_	_	_	_	_
15	light-independent	_	_	JJ	_	_	_	_	_
16	side	_	_	NN	_	_	_	_	_
17	effects	_	_	NNS	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	is	_	_	VBZ	_	_	_	_	_
20	non-invasive	_	_	JJ	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	site-specific	_	_	JJ	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	i.	_	_	FW	_	_	_	_	_
25	e.	_	_	FW	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	limited	_	_	VBN	_	_	_	_	_
28	to	_	_	TO	_	_	_	_	_
29	the	_	_	DT	_	_	_	_	_
30	tumor	_	_	NN	_	_	_	_	_
31	upon	_	_	IN	_	_	_	_	_
32	which	_	_	WDT	_	_	_	_	_
33	light	_	_	NN	_	_	_	_	_
34	is	_	_	VBZ	_	_	_	_	_
35	directed	_	_	VBN	_	_	_	_	_
36	,	_	_	,	_	_	_	_	_
37	typically	_	_	RB	_	_	_	_	_
38	via	_	_	IN	_	_	_	_	_
39	fiber	_	_	NN	_	_	_	_	_
40	optic	_	_	JJ	_	_	_	_	_
41	networks	_	_	NNS	_	_	_	_	_
42	.	_	_	.	_	_	_	_	_


1	Moreover	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	PDT	_	_	NNP	_	_	_	_	_
4	can	_	_	MD	_	_	_	_	_
5	often	_	_	RB	_	_	_	_	_
6	overcome	_	_	VB	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	innate	_	_	JJ	_	_	_	_	_
9	or	_	_	CC	_	_	_	_	_
10	acquired	_	_	VBN	_	_	_	_	_
11	resistance	_	_	NN	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	other	_	_	JJ	_	_	_	_	_
14	therapies	_	_	NNS	_	_	_	_	_
15	that	_	_	WDT	_	_	_	_	_
16	many	_	_	JJ	_	_	_	_	_
17	tumors	_	_	NNS	_	_	_	_	_
18	exhibit	_	_	VBP	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	pre-existing	_	_	JJ	_	_	_	_	_
5	administered	_	_	VBN	_	_	_	_	_
6	sensitizers	_	_	NNS	_	_	_	_	_
7	such	_	_	JJ	_	_	_	_	_
8	as	_	_	IN	_	_	_	_	_
9	Photofrin®	_	_	NNP	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	pro-sensitizers	_	_	NNS	_	_	_	_	_
12	have	_	_	VBP	_	_	_	_	_
13	been	_	_	VBN	_	_	_	_	_
14	developed	_	_	VBN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	one	_	_	CD	_	_	_	_	_
17	common	_	_	JJ	_	_	_	_	_
18	example	_	_	NN	_	_	_	_	_
19	being	_	_	VBG	_	_	_	_	_
20	5-aminolevulinic	_	_	JJ	_	_	_	_	_
21	acid	_	_	NN	_	_	_	_	_
22	(	_	_	-LRB-	_	_	_	_	_
23	ALA	_	_	NNP	_	_	_	_	_
24	)	_	_	-RRB-	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	Upon	_	_	IN	_	_	_	_	_
2	entering	_	_	VBG	_	_	_	_	_
3	cancer	_	_	NN	_	_	_	_	_
4	cells	_	_	NNS	_	_	_	_	_
5	via	_	_	IN	_	_	_	_	_
6	an	_	_	DT	_	_	_	_	_
7	amino	_	_	JJ	_	_	_	_	_
8	acid	_	_	NN	_	_	_	_	_
9	transporter	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	ALA	_	_	NNP	_	_	_	_	_
12	is	_	_	VBZ	_	_	_	_	_
13	metabolized	_	_	VBN	_	_	_	_	_
14	to	_	_	TO	_	_	_	_	_
15	protoporphyrin	_	_	NN	_	_	_	_	_
16	IX	_	_	NNP	_	_	_	_	_
17	(	_	_	-LRB-	_	_	_	_	_
18	PpIX	_	_	NNP	_	_	_	_	_
19	)	_	_	-RRB-	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	active	_	_	JJ	_	_	_	_	_
23	PS	_	_	NN	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	via	_	_	IN	_	_	_	_	_
26	the	_	_	DT	_	_	_	_	_
27	heme	_	_	NN	_	_	_	_	_
28	biosynthetic	_	_	JJ	_	_	_	_	_
29	pathway	_	_	NN	_	_	_	_	_
30	,	_	_	,	_	_	_	_	_
31	PpIX	_	_	NNP	_	_	_	_	_
32	accumulating	_	_	VBG	_	_	_	_	_
33	initially	_	_	RB	_	_	_	_	_
34	in	_	_	IN	_	_	_	_	_
35	mitochondria	_	_	NN	_	_	_	_	_
36	.	_	_	.	_	_	_	_	_


1	For	_	_	IN	_	_	_	_	_
2	rapid	_	_	JJ	_	_	_	_	_
3	proliferative	_	_	JJ	_	_	_	_	_
4	needs	_	_	NNS	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	tumor	_	_	NN	_	_	_	_	_
7	cells	_	_	NNS	_	_	_	_	_
8	are	_	_	VBP	_	_	_	_	_
9	more	_	_	RBR	_	_	_	_	_
10	active	_	_	JJ	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	heme	_	_	NN	_	_	_	_	_
13	synthesis	_	_	NN	_	_	_	_	_
14	than	_	_	IN	_	_	_	_	_
15	normal	_	_	JJ	_	_	_	_	_
16	counterparts	_	_	NNS	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	acting	_	_	VBG	_	_	_	_	_
5	as	_	_	IN	_	_	_	_	_
6	a	_	_	DT	_	_	_	_	_
7	PDT	_	_	NNP	_	_	_	_	_
8	sensitizer	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	ALA-induced	_	_	JJ	_	_	_	_	_
11	PpIX	_	_	NNP	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	like	_	_	IN	_	_	_	_	_
14	that	_	_	DT	_	_	_	_	_
15	induced	_	_	VBN	_	_	_	_	_
16	by	_	_	IN	_	_	_	_	_
17	more	_	_	JJR	_	_	_	_	_
18	lipophilic	_	_	JJ	_	_	_	_	_
19	ALA	_	_	NN	_	_	_	_	_
20	esters	_	_	NNS	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	e.	_	_	FW	_	_	_	_	_
23	g.	_	_	FW	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	Hexvix	_	_	NNP	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	can	_	_	MD	_	_	_	_	_
28	serve	_	_	VB	_	_	_	_	_
29	as	_	_	IN	_	_	_	_	_
30	a	_	_	DT	_	_	_	_	_
31	highly	_	_	RB	_	_	_	_	_
32	effective	_	_	JJ	_	_	_	_	_
33	fluorophore	_	_	NN	_	_	_	_	_
34	for	_	_	IN	_	_	_	_	_
35	image-guided	_	_	JJ	_	_	_	_	_
36	tumor	_	_	NN	_	_	_	_	_
37	resection	_	_	NN	_	_	_	_	_
38	.	_	_	.	_	_	_	_	_


1	Many	_	_	JJ	_	_	_	_	_
2	cancer	_	_	NN	_	_	_	_	_
3	cells	_	_	NNS	_	_	_	_	_
4	exhibit	_	_	VBP	_	_	_	_	_
5	an	_	_	DT	_	_	_	_	_
6	intrinsic	_	_	JJ	_	_	_	_	_
7	or	_	_	CC	_	_	_	_	_
8	acquired	_	_	VBN	_	_	_	_	_
9	resistance	_	_	NN	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	radiotherapy	_	_	NN	_	_	_	_	_
12	or	_	_	CC	_	_	_	_	_
13	chemotherapy	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	resistance	_	_	NN	_	_	_	_	_
17	to	_	_	TO	_	_	_	_	_
18	PDT	_	_	NNP	_	_	_	_	_
19	has	_	_	VBZ	_	_	_	_	_
20	also	_	_	RB	_	_	_	_	_
21	been	_	_	VBN	_	_	_	_	_
22	demonstrated	_	_	VBN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	For	_	_	IN	_	_	_	_	_
2	ALA-PDT	_	_	NNP	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	one	_	_	CD	_	_	_	_	_
5	notable	_	_	JJ	_	_	_	_	_
6	resistance	_	_	NN	_	_	_	_	_
7	mechanism	_	_	NN	_	_	_	_	_
8	involves	_	_	VBZ	_	_	_	_	_
9	efflux	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	newly	_	_	RB	_	_	_	_	_
12	synthesized	_	_	VBN	_	_	_	_	_
13	PpIX	_	_	NNP	_	_	_	_	_
14	via	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	plasma	_	_	NN	_	_	_	_	_
17	membrane	_	_	NN	_	_	_	_	_
18	transporter	_	_	NN	_	_	_	_	_
19	ABCG2	_	_	NNP	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	Another	_	_	DT	_	_	_	_	_
2	important	_	_	JJ	_	_	_	_	_
3	mechanism	_	_	NN	_	_	_	_	_
4	involves	_	_	VBZ	_	_	_	_	_
5	nitric	_	_	NN	_	_	_	_	_
6	oxide	_	_	NN	_	_	_	_	_
7	(	_	_	-LRB-	_	_	_	_	_
8	NO	_	_	NN	_	_	_	_	_
9	)	_	_	-RRB-	_	_	_	_	_
10	generated	_	_	VBN	_	_	_	_	_
11	by	_	_	IN	_	_	_	_	_
12	constitutive	_	_	JJ	_	_	_	_	_
13	and/or	_	_	NN	_	_	_	_	_
14	PDT	_	_	NNP	_	_	_	_	_
15	stress-upregulated	_	_	JJ	_	_	_	_	_
16	inducible	_	_	JJ	_	_	_	_	_
17	nitric	_	_	NN	_	_	_	_	_
18	oxide	_	_	NN	_	_	_	_	_
19	synthase	_	_	NN	_	_	_	_	_
20	(	_	_	-LRB-	_	_	_	_	_
21	iNOS/NOS2	_	_	NNP	_	_	_	_	_
22	)	_	_	-RRB-	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	NO	_	_	UH	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	bioactive	_	_	JJ	_	_	_	_	_
5	free	_	_	JJ	_	_	_	_	_
6	radical	_	_	JJ	_	_	_	_	_
7	molecule	_	_	NN	_	_	_	_	_
8	(	_	_	-LRB-	_	_	_	_	_
9	1	_	_	CD	_	_	_	_	_
10	–	_	_	TO	_	_	_	_	_
11	2	_	_	CD	_	_	_	_	_
12	sec	_	_	NN	_	_	_	_	_
13	lifetime	_	_	NN	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	water	_	_	NN	_	_	_	_	_
16	)	_	_	-RRB-	_	_	_	_	_
17	that	_	_	WDT	_	_	_	_	_
18	diffuses	_	_	VBZ	_	_	_	_	_
19	freely	_	_	RB	_	_	_	_	_
20	on	_	_	IN	_	_	_	_	_
21	its	_	_	PRP$	_	_	_	_	_
22	own	_	_	JJ	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	similar	_	_	JJ	_	_	_	_	_
26	to	_	_	TO	_	_	_	_	_
27	oxygen	_	_	NN	_	_	_	_	_
28	(	_	_	-LRB-	_	_	_	_	_
29	O2	_	_	NN	_	_	_	_	_
30	)	_	_	-RRB-	_	_	_	_	_
31	,	_	_	,	_	_	_	_	_
32	tends	_	_	VBZ	_	_	_	_	_
33	to	_	_	TO	_	_	_	_	_
34	partition	_	_	VB	_	_	_	_	_
35	into	_	_	IN	_	_	_	_	_
36	hydrophobic	_	_	JJ	_	_	_	_	_
37	regions	_	_	NNS	_	_	_	_	_
38	of	_	_	IN	_	_	_	_	_
39	cells	_	_	NNS	_	_	_	_	_
40	,	_	_	,	_	_	_	_	_
41	e.	_	_	FW	_	_	_	_	_
42	g.	_	_	FW	_	_	_	_	_
43	,	_	_	,	_	_	_	_	_
44	cell	_	_	NN	_	_	_	_	_
45	membranes	_	_	NNS	_	_	_	_	_
46	.	_	_	.	_	_	_	_	_


1	At	_	_	IN	_	_	_	_	_
2	relatively	_	_	RB	_	_	_	_	_
3	low	_	_	JJ	_	_	_	_	_
4	steady	_	_	JJ	_	_	_	_	_
5	state	_	_	NN	_	_	_	_	_
6	levels	_	_	NNS	_	_	_	_	_
7	(	_	_	-LRB-	_	_	_	_	_
8	e.	_	_	FW	_	_	_	_	_
9	g.	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	50	_	_	CD	_	_	_	_	_
12	–	_	_	TO	_	_	_	_	_
13	300	_	_	CD	_	_	_	_	_
14	nM	_	_	NN	_	_	_	_	_
15	range	_	_	NN	_	_	_	_	_
16	)	_	_	-RRB-	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	NO	_	_	NNP	_	_	_	_	_
19	is	_	_	VBZ	_	_	_	_	_
20	known	_	_	VBN	_	_	_	_	_
21	to	_	_	TO	_	_	_	_	_
22	play	_	_	VB	_	_	_	_	_
23	a	_	_	DT	_	_	_	_	_
24	key	_	_	JJ	_	_	_	_	_
25	signaling	_	_	VBG	_	_	_	_	_
26	role	_	_	NN	_	_	_	_	_
27	in	_	_	IN	_	_	_	_	_
28	survival	_	_	NN	_	_	_	_	_
29	,	_	_	,	_	_	_	_	_
30	migration	_	_	NN	_	_	_	_	_
31	,	_	_	,	_	_	_	_	_
32	and	_	_	CC	_	_	_	_	_
33	drug	_	_	NN	_	_	_	_	_
34	resistance	_	_	NN	_	_	_	_	_
35	of	_	_	IN	_	_	_	_	_
36	many	_	_	JJ	_	_	_	_	_
37	different	_	_	JJ	_	_	_	_	_
38	cancer	_	_	NN	_	_	_	_	_
39	cells	_	_	NNS	_	_	_	_	_
40	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	contrasts	_	_	VBZ	_	_	_	_	_
3	with	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	cytotoxic	_	_	JJ	_	_	_	_	_
6	effects	_	_	NNS	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	NO	_	_	NN	_	_	_	_	_
9	produced	_	_	VBN	_	_	_	_	_
10	at	_	_	IN	_	_	_	_	_
11	much	_	_	RB	_	_	_	_	_
12	higher	_	_	JJR	_	_	_	_	_
13	levels	_	_	NNS	_	_	_	_	_
14	(	_	_	-LRB-	_	_	_	_	_
15	≥1	_	_	CD	_	_	_	_	_
16	µM	_	_	NN	_	_	_	_	_
17	)	_	_	-RRB-	_	_	_	_	_
18	by	_	_	IN	_	_	_	_	_
19	activated	_	_	VBN	_	_	_	_	_
20	macrophages	_	_	NNS	_	_	_	_	_
21	during	_	_	IN	_	_	_	_	_
22	an	_	_	DT	_	_	_	_	_
23	inflammatory	_	_	JJ	_	_	_	_	_
24	response	_	_	NN	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	e.	_	_	FW	_	_	_	_	_
27	g.	_	_	FW	_	_	_	_	_
28	,	_	_	,	_	_	_	_	_
29	to	_	_	TO	_	_	_	_	_
30	infection	_	_	NN	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	previous	_	_	JJ	_	_	_	_	_
3	work	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	we	_	_	PRP	_	_	_	_	_
6	discovered	_	_	VBD	_	_	_	_	_
7	that	_	_	IN	_	_	_	_	_
8	various	_	_	JJ	_	_	_	_	_
9	cancer	_	_	NN	_	_	_	_	_
10	cell	_	_	NN	_	_	_	_	_
11	lines	_	_	NNS	_	_	_	_	_
12	significantly	_	_	RB	_	_	_	_	_
13	upregulate	_	_	VBD	_	_	_	_	_
14	cytoprotective	_	_	JJ	_	_	_	_	_
15	iNOS	_	_	NN	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	NO	_	_	NNP	_	_	_	_	_
18	after	_	_	IN	_	_	_	_	_
19	a	_	_	DT	_	_	_	_	_
20	moderate	_	_	JJ	_	_	_	_	_
21	photodynamic	_	_	JJ	_	_	_	_	_
22	challenge	_	_	NN	_	_	_	_	_
23	sensitized	_	_	VBN	_	_	_	_	_
24	by	_	_	IN	_	_	_	_	_
25	ALA-induced	_	_	NNP	_	_	_	_	_
26	PpIX	_	_	NNP	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	iNOS/NO	_	_	NNP	_	_	_	_	_
3	induction	_	_	NN	_	_	_	_	_
4	in	_	_	IN	_	_	_	_	_
5	PDT-surviving	_	_	JJ	_	_	_	_	_
6	(	_	_	-LRB-	_	_	_	_	_
7	still	_	_	RB	_	_	_	_	_
8	attached	_	_	VBN	_	_	_	_	_
9	)	_	_	-RRB-	_	_	_	_	_
10	cells	_	_	NNS	_	_	_	_	_
11	was	_	_	VBD	_	_	_	_	_
12	relatively	_	_	RB	_	_	_	_	_
13	rapid	_	_	JJ	_	_	_	_	_
14	after	_	_	IN	_	_	_	_	_
15	irradiation	_	_	NN	_	_	_	_	_
16	(	_	_	-LRB-	_	_	_	_	_
17	2	_	_	CD	_	_	_	_	_
18	–	_	_	TO	_	_	_	_	_
19	3	_	_	CD	_	_	_	_	_
20	h	_	_	NN	_	_	_	_	_
21	)	_	_	-RRB-	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	prolonged	_	_	VBN	_	_	_	_	_
24	(	_	_	-LRB-	_	_	_	_	_
25	at	_	_	IN	_	_	_	_	_
26	least	_	_	JJS	_	_	_	_	_
27	24	_	_	CD	_	_	_	_	_
28	h	_	_	NN	_	_	_	_	_
29	)	_	_	-RRB-	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	Importantly	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	these	_	_	DT	_	_	_	_	_
4	cells	_	_	NNS	_	_	_	_	_
5	exhibited	_	_	VBD	_	_	_	_	_
6	a	_	_	DT	_	_	_	_	_
7	more	_	_	RBR	_	_	_	_	_
8	aggressive	_	_	JJ	_	_	_	_	_
9	growth	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	migratory	_	_	JJ	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	invasive	_	_	JJ	_	_	_	_	_
15	phenotype	_	_	NN	_	_	_	_	_
16	than	_	_	IN	_	_	_	_	_
17	non-photostressed	_	_	JJ	_	_	_	_	_
18	controls	_	_	NNS	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	this	_	_	DT	_	_	_	_	_
22	was	_	_	VBD	_	_	_	_	_
23	suppressed	_	_	VBN	_	_	_	_	_
24	by	_	_	IN	_	_	_	_	_
25	inhibition	_	_	NN	_	_	_	_	_
26	of	_	_	IN	_	_	_	_	_
27	iNOS	_	_	NN	_	_	_	_	_
28	or	_	_	CC	_	_	_	_	_
29	by	_	_	IN	_	_	_	_	_
30	NO	_	_	DT	_	_	_	_	_
31	scavenging	_	_	NN	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	postulated	_	_	VBD	_	_	_	_	_
3	that	_	_	IN	_	_	_	_	_
4	induced	_	_	VBN	_	_	_	_	_
5	diffusible	_	_	JJ	_	_	_	_	_
6	NO	_	_	NN	_	_	_	_	_
7	from	_	_	IN	_	_	_	_	_
8	PDT-targeted	_	_	JJ	_	_	_	_	_
9	cells	_	_	NNS	_	_	_	_	_
10	might	_	_	MD	_	_	_	_	_
11	elicit	_	_	VB	_	_	_	_	_
12	a	_	_	DT	_	_	_	_	_
13	pro-growth/migratory	_	_	JJ	_	_	_	_	_
14	response	_	_	NN	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	non-	_	_	JJ	_	_	_	_	_
17	or	_	_	CC	_	_	_	_	_
18	minimally-targeted	_	_	JJ	_	_	_	_	_
19	bystander	_	_	NN	_	_	_	_	_
20	cells	_	_	NNS	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	an	_	_	DT	_	_	_	_	_
3	actual	_	_	JJ	_	_	_	_	_
4	tumor	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	such	_	_	JJ	_	_	_	_	_
7	targeting	_	_	VBG	_	_	_	_	_
8	diversity	_	_	NN	_	_	_	_	_
9	might	_	_	MD	_	_	_	_	_
10	result	_	_	VB	_	_	_	_	_
11	from	_	_	IN	_	_	_	_	_
12	uneven	_	_	JJ	_	_	_	_	_
13	PS	_	_	NN	_	_	_	_	_
14	distribution	_	_	NN	_	_	_	_	_
15	due	_	_	JJ	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	irregularities	_	_	NNS	_	_	_	_	_
18	in	_	_	IN	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	tumor	_	_	NN	_	_	_	_	_
21	microvasculature	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	Using	_	_	VBG	_	_	_	_	_
2	photosensitized	_	_	VBN	_	_	_	_	_
3	prostate	_	_	NN	_	_	_	_	_
4	cancer	_	_	NN	_	_	_	_	_
5	PC3	_	_	NN	_	_	_	_	_
6	cells	_	_	NNS	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	we	_	_	PRP	_	_	_	_	_
9	recently	_	_	RB	_	_	_	_	_
10	observed	_	_	VBD	_	_	_	_	_
11	NO-mediated	_	_	JJ	_	_	_	_	_
12	hyper-aggressive	_	_	JJ	_	_	_	_	_
13	bystander	_	_	NN	_	_	_	_	_
14	effects	_	_	NNS	_	_	_	_	_
15	for	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	first	_	_	JJ	_	_	_	_	_
18	time	_	_	NN	_	_	_	_	_
19	in	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	context	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	PDT	_	_	NNP	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	present	_	_	JJ	_	_	_	_	_
4	study	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	we	_	_	PRP	_	_	_	_	_
7	compared	_	_	VBD	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	ability	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	four	_	_	CD	_	_	_	_	_
12	PDT-treated	_	_	JJ	_	_	_	_	_
13	cancer	_	_	NN	_	_	_	_	_
14	lines	_	_	NNS	_	_	_	_	_
15	(	_	_	-LRB-	_	_	_	_	_
16	melanoma	_	_	NN	_	_	_	_	_
17	BLM	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	glioblastoma	_	_	NN	_	_	_	_	_
20	U87	_	_	NN	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	breast	_	_	NN	_	_	_	_	_
23	MDA-MB-231	_	_	NN	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	prostate	_	_	NN	_	_	_	_	_
27	PC3	_	_	NN	_	_	_	_	_
28	)	_	_	-RRB-	_	_	_	_	_
29	to	_	_	TO	_	_	_	_	_
30	stimulate	_	_	VB	_	_	_	_	_
31	NO-dependent	_	_	JJ	_	_	_	_	_
32	aggressiveness	_	_	NN	_	_	_	_	_
33	in	_	_	IN	_	_	_	_	_
34	bystander	_	_	NN	_	_	_	_	_
35	cells	_	_	NNS	_	_	_	_	_
36	of	_	_	IN	_	_	_	_	_
37	the	_	_	DT	_	_	_	_	_
38	same	_	_	JJ	_	_	_	_	_
39	type	_	_	NN	_	_	_	_	_
40	.	_	_	.	_	_	_	_	_

